A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

NCT06557174 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Interventions

DRUG: IMC-002
DRUG: mycophenolate mofetil， MMF

Sponsor

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.